Extracorporeal Photopheresis : : Cellular Photoimmunotherapy / / ed. by Hildegard T. Greinix, Robert Knobler.
Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy for cancer, namely cutaneous T-cell lymphoma, and has demonstrated efficacy in various diseases that have a suspected involvement of pathogenic T-cells including prevention and treatment of acute and chronic gra...
Saved in:
Superior document: | Title is part of eBook package: De Gruyter DGBA Backlist Complete English Language 2000-2014 PART1 |
---|---|
MitwirkendeR: | |
HerausgeberIn: | |
Place / Publishing House: | Berlin ;, Boston : : De Gruyter, , [2012] ©2012 |
Year of Publication: | 2012 |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (215 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Other title: | Frontmatter -- Preface -- Content -- Authors Index -- Section 1: History of Extracorporeal Photopheresis -- Section 2: Technical Aspects -- Section 3: Mechanisms of Action of ECP -- Section 4: Extracorporeal Photopheresis in Acute Graft-versus-Host Disease -- Section 5: Extracorporeal Photopheresis in Chronic Graft-versus-Host Disease -- Section 6: ECP for the Prevention of Graft-versus-Host Disease -- Section 7: ECP in Cutaneous T Cell Lymphoma -- Section 8: ECP in Scleroderma and Other Skin Diseases -- Section 9: ECP in Crohn's Disease -- Section 10: Extracorporeal Photopheresis after Solid Organ/Tissue Transplantation -- Section 11: ECP in Diabetes Mellitus -- Section 12: Side Effects of Extracorporeal Photopheresis -- Section 13: Summary |
---|---|
Summary: | Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy for cancer, namely cutaneous T-cell lymphoma, and has demonstrated efficacy in various diseases that have a suspected involvement of pathogenic T-cells including prevention and treatment of acute and chronic graft-versus-host disease, organ transplant rejection, selected autoimmune diseases and Sezary syndrome. In ECP, patient’s blood mononuclear cells are collected, exposed to ultraviolet light in the presence of extracorporeally administered liquid 8-methoxypsoralen and reinfused. Besides its considerable efficacy ECP has an exceptional safety profile, does not cause general immunosuppression and thus, does not increase risk of infectious complications and relapse of malignant disease. Exciting preclinical data and clinical observations provide insight into the mechanisms of action of ECP and support its immunomodulatory role. This book will provide an overview on the historical development of ECP, technical aspects for its use in various patient populations including children and adults, novel research findings both in preclinical models and in various patient cohorts and will stimulate further research in organ, tissue and cell transplantation and autoimmune disorders. |
Format: | Mode of access: Internet via World Wide Web. |
ISBN: | 9783110276138 9783110238570 9783110238495 9783110637915 |
DOI: | 10.1515/9783110276138 |
Access: | restricted access |
Hierarchical level: | Monograph |
Statement of Responsibility: | ed. by Hildegard T. Greinix, Robert Knobler. |